Novo Nordisk A/S (NOVO.B)

New feature

Thematic Research

Now you can save results to your research library to reference later, and add custom notes to your insights and share.

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Feb 05, 2025

$86.42

P/E Ratio

27.32

Market Cap

$383.21B

Description
Add to research

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Metrics
Add to research

Overview

  • HQBagsværd, CR
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerNOVO.B
  • Price$86.418909+5.29%

Trading Information

  • Market cap$383.21B
  • Float70.97%
  • Average Daily Volume (1m)4,228,178
  • Average Daily Volume (3m)4,124,139
  • EPS$22.67

Company

  • Revenue$290.40B
  • Rev growth (1yr)25.03%
  • Net income$100.99B
  • Gross margin83.85%
  • EBITDA margin50.95%
  • EBITDA$147.95B
  • EV$2.86T
  • EV/Revenue9.86
  • P/E27.32
  • P/S9.52
  • P/B22.69
Documents
Add to research
Factset Street Account
Wikipedia